CEACAM5 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain CEACAM5 status and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 3 (1 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for non-squamous non-small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and non-squamous non-small cell lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CEACAM5 is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain CEACAM5 status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for acute lymphoblastic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM5 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM5 status and acute myeloid leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for colon adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and colon adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CEACAM5 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for rectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and rectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

CEACAM5 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CEACAM5 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].